Repligen (NASDAQ:RGEN) Coverage Initiated by Analysts at Evercore ISI

Evercore ISI started coverage on shares of Repligen (NASDAQ:RGEN) in a research note released on Tuesday morning, MarketBeat.com reports. The brokerage issued an in-line rating and a $155.00 target price on the biotechnology company’s stock.

RGEN has been the topic of several other reports. Royal Bank of Canada increased their price target on shares of Repligen from $203.00 to $205.00 and gave the company an “outperform” rating in a report on Friday, February 21st. Canaccord Genuity Group increased their target price on shares of Repligen from $165.00 to $170.00 and gave the stock a “hold” rating in a research report on Friday, February 21st. HC Wainwright restated a “buy” rating and set a $180.00 target price on shares of Repligen in a research report on Friday, February 21st. JPMorgan Chase & Co. increased their target price on shares of Repligen from $190.00 to $200.00 and gave the stock an “overweight” rating in a research report on Friday, February 21st. Finally, StockNews.com lowered shares of Repligen from a “hold” rating to a “sell” rating in a research report on Friday, February 21st. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat, Repligen presently has an average rating of “Hold” and a consensus price target of $178.64.

Repligen Stock Down 5.5 %

Repligen stock opened at $144.34 on Tuesday. The stock has a market cap of $8.09 billion, a P/E ratio of -283.02, a P/E/G ratio of 4.54 and a beta of 0.95. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26. Repligen has a twelve month low of $113.50 and a twelve month high of $200.23. The company’s 50-day moving average price is $156.98 and its two-hundred day moving average price is $148.49.

Repligen (NASDAQ:RGEN) last released its quarterly earnings results on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share for the quarter, beating the consensus estimate of $0.41 by $0.03. The firm had revenue of $167.55 million for the quarter, compared to analysts’ expectations of $167.58 million. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. As a group, analysts expect that Repligen will post 1.72 EPS for the current year.

Insider Buying and Selling at Repligen

In related news, Director Margaret Pax bought 250 shares of the business’s stock in a transaction on Monday, March 17th. The shares were purchased at an average price of $150.69 per share, for a total transaction of $37,672.50. Following the completion of the transaction, the director now directly owns 1,043 shares of the company’s stock, valued at approximately $157,169.67. This represents a 31.53 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Company insiders own 1.20% of the company’s stock.

Institutional Trading of Repligen

Hedge funds have recently added to or reduced their stakes in the stock. Signaturefd LLC boosted its position in Repligen by 172.2% in the fourth quarter. Signaturefd LLC now owns 196 shares of the biotechnology company’s stock valued at $28,000 after buying an additional 124 shares in the last quarter. Sava Infond d.o.o. bought a new position in shares of Repligen during the fourth quarter valued at $29,000. Raiffeisen Bank International AG bought a new position in shares of Repligen during the fourth quarter valued at $29,000. Resources Management Corp CT ADV bought a new position in shares of Repligen during the third quarter valued at $37,000. Finally, Quarry LP raised its stake in shares of Repligen by 796.7% during the third quarter. Quarry LP now owns 269 shares of the biotechnology company’s stock valued at $40,000 after acquiring an additional 239 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.